S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

SNDX Syndax Pharmaceuticals Inc

22.50

0.45 (2.04%)

07 May 2024 - Closed

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Syndax Pharmaceuticals Charts.

Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Syndax Pharmaceuticals Charts.

Syndax Pharmaceuticals Inc News

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Saturday 4 May 2024 (3 days ago) • PR Newswire (US)

Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
Wednesday 1 May 2024 (6 days ago) • PR Newswire (US)

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
Thursday 11 April 2024 (4 weeks ago) • PR Newswire (US)

Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
Monday 8 April 2024 (4 weeks ago) • PR Newswire (US)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Saturday 6 April 2024 (1 month ago) • PR Newswire (US)

Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
Thursday 28 March 2024 (1 month ago) • PR Newswire (US)

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
Wednesday 27 March 2024 (1 month ago) • PR Newswire (US)

Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
Monday 18 March 2024 (2 months ago) • PR Newswire (US)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Saturday 2 March 2024 (2 months ago) • PR Newswire (US)

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers
Wednesday 28 February 2024 (2 months ago) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Wednesday 28 February 2024 (2 months ago) • Edgar (US Regulatory)

Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
Wednesday 28 February 2024 (2 months ago) • PR Newswire (US)

More Syndax Pharmaceuticals Inc News Articles

National Australia Bank

AUD vs US Dollar

S&P ASX 300 Metals and M...

Woodside Petroleum

JP Morgan Chase

Australia And New Zealan...

Verizon Communications

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions